Table 3 Comparing characteristics based on the additional treatment needs after second-line treatments in the PDT group
Characteristic | Non-injection free cases, N = 19 | Injection-free cases, N = 5 | P-values |
|---|---|---|---|
At the second-line treatment | |||
Age (years) | 73.0 ± 7.7; 73.0 | 81.4 ± 6.8; 82.0 | 0.042 |
Female | 4 (21.1%) | 0 (0.00%) | 0.479 |
Total number of previous injections | 12.1 ± 7.6; 11.0 | 11.2 ± 3.7; 11.0 | 0.943 |
BCVA (logMAR) | 0.29 ± 0.35; 0.30 | 0.35 ± 0.29; 0.30 | 0.591 |
SRF | 18 (94.7%) | 5 (100%) | 0.242 |
IRF | 4 (21.1%) | 3 (60.0%) | 0.683 |
CVH | 11 (57.9%) | 5 (100%) | 0.747 |
The maximum PED size (μm) | 399.6 ± 291.7; 297.0 | 508.6 ± 238.5; 483.0 | 0.213 |
SRH | 7 (36.8%) | 1 (20.0%) | 0.747 |
Fibrotic scar | 6 (31.6%) | 2 (40.0%) | 0.747 |
CCT (μm) | 244.7 ± 85.6; 233.0 | 243.2 ± 35.3; 236.0 | 0.915 |
CMT (μm) | 396.8 ± 156.2; 353.0 | 360.0 ± 251.8; 246.0 | 0.095 |
The mean of previous treatment intervals (weeks) | 6.3 ± 2.4; 5.7 | 6.7 ± 1.5; 6.7 | 0.595 |
Twelve months after a second-line treatment | |||
BCVA (logMAR) | 0.35 ± 0.42; 0.23 | 0.31 ± 0.29; 0.40 | 0.881 |
CMT (μm) | 298.3 ± 67.2; 276.5 | 216.0 ± 23.3; 215.0 | 0.001 |
The change of BCVA from the baseline (logMAR) | 0.06 ± 0.15; 0.00 | − 0.05 ± 0.27; − 0.05 | 0.318 |
The change of CMT from the baseline (μm) | − 106.6 ± 168.3; -67.5 | − 144.0 ± 243.5; -31.0 | 0.852 |